Paliperidone palmitate - Generic Drug Details

What are the generic drug sources for paliperidone palmitate and what is the scope of freedom to operate?

Paliperidone palmitate is the generic ingredient in four branded drugs marketed by Luye Innomind Pharma and Janssen Pharms, and is included in three NDAs. There are eight patents protecting this compound and one Paragraph IV challenge. Additional information is available in the individual branded drug profile pages.

Paliperidone palmitate has one hundred and eighty-one patent family members in thirty-six countries.

There are twelve drug master file entries for paliperidone palmitate. Three suppliers are listed for this compound. There are five tentative approvals for this compound.

Summary for paliperidone palmitate

International Patents:	181
US Patents:	8
Tradenames:	4
Applicants:	2
NDAs:	3
Drug Master File Entries:	12
Finished Product Suppliers / Packagers:	3
Raw Ingredient (Bulk) Api Vendors:	65
Clinical Trials:	60
Patent Applications:	687
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for paliperidone palmitate
What excipients (inactive ingredients) are in paliperidone palmitate?	paliperidone palmitate excipients list
DailyMed Link:	paliperidone palmitate at DailyMed

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for paliperidone palmitate

Constraining patent/regulatory exclusivity:

12,128,049

Dosage:

SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR

Constraining patent/regulatory exclusivity:

10,143,693

Dosage:

SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR

Constraining patent/regulatory exclusivity:

5,254,556

Dosage:

SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for paliperidone palmitate

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Jiangsu Province Nanjing Brain Hospital	PHASE4
CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.	NA
First Affiliated Hospital Xi'an Jiaotong University	N/A

See all paliperidone palmitate clinical trials

Generic filers with tentative approvals for PALIPERIDONE PALMITATE

Applicant	Application No.	Strength	Dosage Form
			SUSPENSION;EXTENDED RELEASE
		234MG/1.5ML	SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR
		156MG/ML	SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR

The 'tentative' approval signifies that the product meets all FDA standards for marketing, and, but for the patents / regulatory protections, it would approved.

Pharmacology for paliperidone palmitate

Drug Class

Atypical Antipsychotic

Medical Subject Heading (MeSH) Categories for paliperidone palmitate

Antipsychotic Agents

Dopamine D2 Receptor Antagonists

Serotonin 5-HT2 Receptor Antagonists

Anatomical Therapeutic Chemical (ATC) Classes for paliperidone palmitate

N05AX	Other antipsychotics
N05A	ANTIPSYCHOTICS
N05	PSYCHOLEPTICS
N	Nervous system

Paragraph IV (Patent) Challenges for PALIPERIDONE PALMITATE

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
INVEGA TRINZA	Extended-release Injectable Suspension	paliperidone palmitate	273 mg/0.875 mL and 410 mg/1.315 mL	207946	1	2021-07-14
INVEGA TRINZA	Extended-release Injectable Suspension	paliperidone palmitate	819 mg/2.625 mL	207946	1	2021-04-30
INVEGA TRINZA	Extended-release Injectable Suspension	paliperidone palmitate	546 mg/1.75 mL	207946	1	2020-06-24
INVEGA SUSTENNA	Extended-release Injectable Suspension	paliperidone palmitate	39 mg/0.25 mL, 78 mg/0.5 mL, 117 mg/0.75 mL, 156 mg/mL and 234 mg/1.5 mL	022264	1	2017-11-21

US Patents and Regulatory Information for paliperidone palmitate

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Janssen Pharms	INVEGA TRINZA	paliperidone palmitate	SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR	207946-001	May 18, 2015		RX	Yes	Yes	10,143,693
Luye Innomind Pharma	ERZOFRI	paliperidone palmitate	SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR	216352-006	Jul 26, 2024		RX	Yes	Yes	11,666,573
Luye Innomind Pharma	ERZOFRI	paliperidone palmitate	SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR	216352-005	Jul 26, 2024		RX	Yes	Yes	11,666,573
Janssen Pharms	INVEGA HAFYERA	paliperidone palmitate	SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR	207946-006	Aug 30, 2021		RX	Yes	Yes	11,666,697
Luye Innomind Pharma	ERZOFRI	paliperidone palmitate	SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR	216352-001	Jul 26, 2024		RX	Yes	Yes	11,666,573
Janssen Pharms	INVEGA TRINZA	paliperidone palmitate	SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR	207946-004	May 18, 2015		RX	Yes	Yes	10,143,693

Expired US Patents for paliperidone palmitate

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Janssen Pharms	INVEGA SUSTENNA	paliperidone palmitate	SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR	022264-005	Jul 31, 2009	5,352,459*PED
Janssen Pharms	INVEGA SUSTENNA	paliperidone palmitate	SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR	022264-002	Jul 31, 2009	6,555,544*PED
Janssen Pharms	INVEGA SUSTENNA	paliperidone palmitate	SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR	022264-001	Jul 31, 2009	5,254,556*PED
Janssen Pharms	INVEGA SUSTENNA	paliperidone palmitate	SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR	022264-002	Jul 31, 2009	5,352,459*PED
Janssen Pharms	INVEGA SUSTENNA	paliperidone palmitate	SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR	022264-004	Jul 31, 2009	5,254,556*PED
Janssen Pharms	INVEGA TRINZA	paliperidone palmitate	SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR	207946-002	May 18, 2015	6,077,843*PED

International Patents for paliperidone palmitate

Country	Patent Number	Title	Estimated Expiration
South Korea	20170134583	장기간 작용형 주사용 팔리페리돈 에스테르에 대한 누락된 용량에 대한 투여 계획
Slovenia	2234617
World Intellectual Property Organization (WIPO)	2022111859
Poland	3744326
Slovenia	4025188
Australia	2024202306

Supplementary Protection Certificates for paliperidone palmitate

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0368388	07C0044	France		PRODUCT NAME: PALIPERIDONE; REGISTRATION NO/DATE IN FRANCE: EU/1/07/395/01 DU 20070626; REGISTRATION NO/DATE AT EEC: EU/1/07/395/01 DU 20070625
0904081	SPC/GB11/044	United Kingdom		PRODUCT NAME: PALIPERIDONE PALMITATE; REGISTERED: UK EU/1/11/672/001 20110304; UK EU/1/11/672/002 20110304; UK EU/1/11/672/003 20110304; UK EU/1/11/672/004 20110304; UK EU/1/11/672/005 20110304; UK EU/1/11/672/006 20110304
0904081	2011/021	Ireland		PRODUCT NAME: PALIPERIDONE PALMITATE ESTER; REGISTRATION NO/DATE: EU/1/11/672/001-006 20110304
0368388	SPC/GB07/065	United Kingdom		PRODUCT NAME: PALIPERIDONE, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT; REGISTERED: UK EU/1/07/395/001 20070625; UK EU/1/07/395/002 20070625; UK EU/1/07/395/003 20070625; UK EU/1/07/395/004 20070625; UK EU/1/07/395/005 20070625; UK EU/1/07/395/006 20070625; UK EU/1/07/395/007 20070625; UK EU/1/07/395/008 20070625; UK EU/1/07/395/009 20070625; UK EU/1/07/395/010 20070625; UK EU/1/07/395/011 20070625; UK EU/1/07/395/012 20070625; UK EU/1/07/395/013 20070625; UK EU/1/07/395/014 20070625; UK EU/1/07/395/015 20070625; UK EU/1/07/395/016 20070625; UK EU/1/07/395/017 20070625; UK EU/1/07/395/018 20070625; UK EU/1/07/395/019 20070625; UK EU/1/07/395/020 20070625; UK EU/1/07/395/021
0904081	11C0035	France		PRODUCT NAME: PALMITATE DE PALIPERIDONE; REGISTRATION NO/DATE: EU/1/11/672/001 20110304

Paliperidone palmitate Market Analysis and Financial Projection

Last updated: February 12, 2026

What Are the Market Dynamics for Paliperidone Palmitate?

Paliperidone palmitate is an injectable long-acting atypical antipsychotic for schizophrenia treatment. The drug's market is influenced by factors including increasing schizophrenia prevalence, shifts toward long-acting injectables (LAIs), and regulatory approvals.

Key Market Drivers

• Prevalence of Schizophrenia: Expected global incidence exceeds 20 million cases, with rising recognition in developing regions.
• Patient Compliance: LAIs like paliperidone palmitate improve adherence, critical in schizophrenia management.
• Regulatory Approvals & Reimbursements: FDA approval in 2015 for schizophrenia; coverage decisions favor distribution.
• Competitive Landscape: Other LAIs, including risperidone microspheres, aripiprazole monohydrate, and newer agents, influence market share.

Market Challenges

• High Cost: Price point around $1,200-$1,500 per injection increases barriers for healthcare systems and patients.
• Administration Requirements: Monthly injections require healthcare visits, affecting patient acceptance.
• Generic Entry: Patent expiries may lead to biosimilars, pressuring prices and margins; patent expiration for the original formulation was in 2020, with some formulations extending protection through secondary patents.

Regional Market Variations

• North America: Largest market, driven by healthcare infrastructure, recycling of antipsychotic therapies, and robust reimbursement.
• Europe: Similar trends, with some countries favoring oral over injectable forms due to cultural and regulatory factors.
• Asia-Pacific: Fastest growth rate, driven by rising mental health awareness, new healthcare policies, and expanding pharmaceutical infrastructure.

What Is the Financial Trajectory of Paliperidone Palmitate?

The financial outlook combines current sales data, growth projections, and the impact of patent protections and generic potential.

Current Market Revenue

• In 2022, the global sales of paliperidone palmitate formulations were estimated near $1.2 billion, with shares attributed to Pfizer (brand name Invega Sustenna) and Johnson & Johnson (Invega Trinza).
• Pfizer holds an approximately 60% market share in North America; Janssen's share is about 30%, with other regional providers comprising the remaining 10%.

Revenue Growth

• Compound annual growth rate (CAGR) from 2017 to 2022 stands at roughly 8%, driven by expanding indications, increased adoption, and new brand launches.
• Future projections suggest a CAGR of 5-7% until 2027, with potential acceleration in emerging markets.

Pricing Trends

• Pricing pressures from biosimilars and generics are expected to reduce per-unit costs by 10-15% over the next five years.
• Market exclusivity protections may extend until 2024-2025, depending on jurisdiction and patent extensions.

Expense and Investment Outlook

• R&D investment in long-acting injectables and biosimilars is approximately $600 million annually across the industry.
• Companies prioritize formulations with extended dosing intervals (e.g., quarterly or biannual injections) to capture premium segments.

What Factors Influence Future Market and Financial Outcomes?

9 key factors shape the future of paliperidone palmitate:

1. Patent Status & Biosimilar Entry: Patent expiry opens the market for biosimilars, exerting downward pressure on prices.
2. Regulatory Environment: Approvals for biosimilars could trigger market share redistribution.
3. Reimbursement Policies: Payers' reimbursement strategies influence adoption rates; shifts toward value-based care shape formulary decisions.
4. Market Penetration in Emerging Countries: Growth hinges on healthcare infrastructure development, insurance coverage, and cultural acceptance.
5. Innovation in Formulation: Development of less frequent injections (quarterly, biannual) enhances patient compliance.
6. Competition from New Agents: Novel antipsychotics with better efficacy or side-effect profiles could impact demand.
7. Long-term Patient Outcomes: Robust evidence demonstrating cost-effectiveness and improved adherence strengthens market position.

How Do Comparative Drugs and Market Trends Impact Financial Projections?

Drug/Platform	Market Share (2022)	Price Point	Dosing Frequency	Patent Status	Notes
Invega Sustenna	60%	$1,200 per injection	Monthly	Patent until 2025	Leading in North America
Invega Trinza	30%	$1,800 per injection	Quarterly	Patent until 2025	Extend patient compliance options
Risperdal Consta	5%	$1,000 per injection	Biweekly/Monthly	Patent lapsed	Biosimilar competition emerging
Others (biosimilars)	5%	Price varies	Variable	Entry post-2024	Market expansion expected post-patent expiry

What’s the Outlook for Long-Term Financial Success?

• The market is likely to stabilize around $1.2-$1.5 billion annually through 2027.
• Revenue growth hinges on biosimilar competition, regulatory approvals for new formulations, and expanding markets.
• Price reductions related to biosimilars may impact revenues; however, increased volume in emerging markets could offset margins declines.
• Strategic investments into formulations with less frequent dosing and improved delivery systems aim to sustain premium pricing.
• The adoption rate in countries without strict drug formularies could accelerate revenues, especially as mental health awareness increases globally.

Key Takeaways

• Paliperidone palmitate remains a significant part of the schizophrenia long-acting injectable market, with approximately $1.2 billion in global sales in 2022.
• Market growth depends on approval and uptake of biosimilars post-2024, regional healthcare policies, and innovation in drug delivery.
• Revenue prospects are favorably influenced by increasing schizophrenia prevalence, compliance improvements due to LAIs, and expanding mental health initiatives.
• Patent expiries threaten to decrease prices; companies invest in formulations with longer dosing intervals to maintain value.
• Emerging markets present long-term growth opportunities, compensating for saturation in mature markets.

FAQs

1. How soon will biosimilar versions of paliperidone palmitate enter the market?
Biosimilar entry is expected after patent expiration, which for the primary formulation occurred in 2020, but regulatory approvals and market readiness may delay the start until 2024 or later.

2. Which regions present the highest growth potential?
Asia-Pacific markets are projected to grow fastest due to increasing healthcare infrastructure, rising awareness, and expanding insurance coverage.

3. How does dosing frequency influence market share?
Longer dosing intervals, such as quarterly or biannual injections, improve patient adherence and preference, increasing adoption over monthly formulations.

4. Will new antipsychotic drugs threaten paliperidone palmitate?
Yes, if new agents demonstrate superior efficacy, safety, or cost-effectiveness, they could displace current LAIs. However, long-established safety profiles and clinical familiarity sustain current usage.

5. What are the main factors driving price reductions?
Biosimilar competition, patent expirations, and payer negotiations primarily influence declines in drug pricing over the next five years.

---

References

[1] MarketResearch.com. (2022). Global schizophrenia drug market report.
[2] IQVIA. (2022). Prescription Data & Market Trends.
[3] U.S. Food and Drug Administration. (2015). Approval of Invega Sustenna.
[4] Johnson & Johnson. (2021). Corporate Annual Report.
[5] Pfizer. (2022). Oncology & Psychiatry Pipeline Overview.